Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …

Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …

Purpose: Although KRAS represents the most commonly mutated oncogene, it has long
been considered an “undruggable” target. Novel covalent inhibitors selective for the …

KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …

SHP2 mediates the activities of multiple receptor tyrosine kinase signaling and its function in
endothelial processes has been explored extensively. However, genetic studies on the role …

Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine
kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently …

With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …

SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-
receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …